Free Preview — Investor scores & financials for AFYA. Sign up for full buy targets.
Start Free

Is Afya Limited (AFYA) Undervalued? Valuation & Fair Price

At $13.60, 3 of the 4 frameworks would buy Afya Limited today — Warren Buffett, Benjamin Graham, and Peter Lynch rate it Buy and Phil Town (Rule #1) rates it Avoid. Each model calculates its own fair value and margin of safety; create a free account to see the exact buy price behind every verdict.

AF

Afya Limited

AFYA

Consumer Defensive · Education & Training Services · NASDAQ

$13.60

P/E 8.5×

CEO

Virgilio Deloy Capobianco Gibbon

Sector

Consumer Defensive

Industry

Education & Training Services

Afya Limited, operating through its subsidiaries, is a prominent medical education provider in Brazil. The company delivers a comprehensive array of educational products and services primarily focused on the medical field, encompassing medical schools, preparatory courses for medical residency, advanced graduate studies, and various other programs tailored for medical professionals at all career stages. These offerings are available across its proprietary network and are also extended to external medical institutions. Beyond traditional education, Afya also offers digital health services through a subscription-based platform, accessible via a mobile app and website. This platform is specifically designed to assist healthcare practitioners and students with clinical decision-making by providing essential tools such as medical calculators, reference charts, up-to-date content, prescription guidance, clinical scoring systems, details on medical procedures, and laboratory examination information. While strong in medicine, Afya's educational portfolio spans a broader spectrum of health sciences, including dentistry, nursing, radiology, psychology, pharmacy, physical education, physiotherapy, nutrition, and biomedicine. Furthermore, the company extends its academic offerings beyond healthcare to include undergraduate and postgraduate degree programs in diverse subjects like business administration, accounting, law, civil engineering, industrial engineering, and pedagogy. The company further enhances its educational ecosystem by providing specialized postgraduate medical programs, both printed and digital educational materials, an online medical learning platform, and hands-on medical training opportunities. As of December 31, 2021, Afya maintained an extensive network of 46 undergraduate and graduate medical school campuses, which included 30 operational undergraduate units and five approved units. This infrastructure supported a total capacity of 2,731 medical school seats, with 2,481 actively operating and an additional 278 seats approved for future use. Established in 1999, Afya Limited is headquartered in Nova Lima, Brazil.

Investor scorecard

How the four investors rate Afya Limited

3 of 4 frameworks lean Buy

Warren Buffett
83%Buy
Benjamin Graham
79%Strong Buy
Peter Lynch
89%Strong Buy
Phil Town (Rule #1)
82%Avoid

Investor model analysis

Details locked

At $13.60, 3 of 4 frameworks say Buy

Business Quality83/100

Intrinsic Value (DCF)

Warren Buffett's valuation model · select an investor above to switch

Intrinsic Value

Locked — upgrade to view

Buy Below

Locked — upgrade to view

Strong Buy

Locked — upgrade to view

Margin of Safety

Locked — upgrade to view

Unlock buy targets with a free account

Get started

Create a free account to see buy targets, full checklists & risk analysis Get started

Insider & congress activity

Are insiders buying AFYA?

Over recent SEC Form 4 filings, AFYA insiders bought $0 and sold $3.2M of stock across 19 open-market trades. Insiders sell for many reasons, but they buy for one.

Bought $0Sold $3.2M
Recent open-market insider trades for AFYA
InsiderActionSharesValueDate
Junior Lelio De SouzaVice PresidentSell36,204$543KJul 1, 2026
Basolli Gomiero MirellaVice PresidentSell10,000$148KJun 26, 2026
Junior Lelio De SouzaVice PresidentSell41,541$623KJun 26, 2026
FERREIRA SANTOS WELDERControllerSell3,325$53KApr 17, 2026
GRIFO DE SOUSA ANIBAL JOSEVP Legal, Comp., & Gov Rel.Sell5,000$77KApr 13, 2026

Source: SEC Form 4 filings. Open-market buys & sells only. Not investment advice.

See the interactive insider chart & every trade

Scenario analysis

Bear, base & bull

Three growth assumptions, three fair values — and where today's price lands

What's working

Key strengths

Identified by Buffett framework analysis

Return on Equity

ROE Quality (Low Leverage)

Debt Levels

Risk factors & concerns — free account

Unlock

Company financials

5-Year Financials

Income statement highlights — annual, USD

Metric20252024202320222021
Revenue$705M
$643M
$559M
$453M
$334M
Rev. Growth+9.7%+14.9%+23.5%+35.5%—
Net Income$143M$123M$75M$73M$43M
Net Margin20.4%19.1%13.4%16.0%13.0%
EPS (Diluted)$1.59$1.36$0.83$0.81$0.46
Free Cash FlowLocked — upgrade to viewLocked — upgrade to viewLocked — upgrade to viewLocked — upgrade to viewLocked — upgrade to view

Full analysis included

See the complete picture for AFYA

Exact buy targets, margin of safety, detailed investor checklists, and risk breakdown — all frameworks, all numbers.

Buy & sell targetsFull checklistRisk breakdown

Free: 3 analyses/month · Pay per stock: $4.99 · Pro: $19.99/mo

More Consumer Defensive stocks

Educational Use Only · Not Financial Advice

Analysis, scores, valuations, and buy zones are derived from publicly documented investor frameworks (Buffett, Lynch, Benjamin Graham, Phil Town) for learning purposes only. They are not recommendations from licensed financial advisors. Past performance does not guarantee future results. Prices may be delayed up to 15 minutes. Always conduct your own research before making any investment decisions.